TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for HYQVIA® as a maintenance therapy for patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Please find the press release here:
Other Articles You May Like
July 1, 2026
LONDC & ANF Launch “Why Behind Your Weakness” Campaign
We’re excited to announce that the Late-Onset Neuromuscular Disease Consortium (LONDC) and ANF launched the…
June 25, 2026
Speaker Series: What is the Nervous System
The nervous system plays a vital role in how your body moves, feels, and functions,…
June 23, 2026
Global Collaboration Sparks Policy Change in Turkey
In early 2025, the Foundation’s International team was presented with an evolving situation in Turkey…